XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis
AUSTIN, Texas, Sept. 13, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced that it has completed the first cohort of its open label pilot study in Atopic Dermatitis (AD). In the first phase of the study, 9 patients received a low dose (200mg …